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A B S T R A C T
Extracellular vesicles (EVs), which are small cell-derived compartments, take part in numerous different phy-
siological processes. The contents of EVs reveal the cell of origin and indicates pathophysiological states in
different diseases. In pregnancy disorders, changes have been reported in the composition, bioactivity and
concentration of placental and non-placental EVs. The purpose of this study was to monitor the effects on EVs in
patients receiving intravenous immunoglobulin (IVIG) or placebo (albumin) treatment due to recurrent preg-
nancy loss (RPL).
In a placebo-controlled trial study of IVIG treatment, plasma collected from 39 women with RPL were in-
vestigated using the Extracellular Vesicle Array (EV Array). Plasma was sampled consecutively (from gestational
week (GW) 5) and the protein phenotypes of the smaller EVs (sEVs) were analyzed for the presence of 34
markers. The levels of sEVs or changes in their levels in early pregnancy were correlated with treatment.
There was statistically significant increased levels of sEVs in patients who received IVIG versus placebo. In
conclusion, the treatment with high-doses of IVIG clearly boosted the production and release of sEVs to the
circulation; however, the biological role of this boost remains to be clarified in further studies.
1. Introduction
Pregnancy loss (PL) is the most common pregnancy complication
happening in approximately 15 % of all pregnancies (Alijotas-Reig and
Garrido-Gimenez, 2013). Recurrent pregnancy loss (RPL) is defined as
either ≥3 consecutive pregnancy losses before gestational week 12 or
as 2 pregnancy losses after normal ultrasound confirmation at week 12.
RPL is estimated to have an incidence of 1–3 % of all couples (Alijotas-
Reig and Garrido-Gimenez, 2013; Wang et al., 2016).
Since immunological disturbances seem to be a risk factor in many
cases of RPL, various immune-therapeutic interventions have been
tested in this context. Intravenous immunoglobulin (IVIG) exhibits a
documented effect in many disorders caused by immunological ab-
normalities (Galeotti et al., 2018; Jolles et al., 2005). IVIG is a pooled
preparation of normal IgG obtained from several thousand healthy
donors. Besides IgG monomers (>96 %), a small percentage of IgG
dimers, IgM and IgA can be found in IVIG preparations (Galeotti et al.,
2018).
IVIG has also been tested in the treatment of women with RPL in
several studies with very diverging results. In the late 1990’s a rando-
mized, double-blinded, placebo-controlled trial of IVIG was performed
(Christiansen et al., 2002). The conclusion of the study was that IVIG
might improve pregnancy outcome although a new placebo-controlled
trial would be needed to confirm the results.
Since this study was published, the understanding of how cells
communicate has undergone a paradigm shift with the recognition of
the role of extracellular vesicles (EVs) in intercellular signaling. EVs are
membrane-bound complexes secreted from cells under both
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physiological and pathological conditions. They contain proteins, nu-
cleic acids and lipids and act as messengers for cell–cell communication
and signaling.
EV is a general term encompassing several different vesicle types,
including exosomes, microvesicles, and apoptotic bodies, released by
cells constitutively or in response to specific stimuli. The EVs are pri-
marily distinguished on the basis of their size with exosomes, micro-
vesicles and apoptotic bodies considered to be 30–100 nm, 100 nm – 1
μm and 1–5 μm, respectively (Raposo and Stoorvogel, 2013). Not only
do these vesicles differ in size, but there are also differences with regard
to their formation and protein content. Microvesicles are released from
the plasma membrane by direct budding or shedding in response to e.g.
cellular activation or stress, whereas exosomes are formed from inter-
nalized endocytic vesicles, and are constitutively secreted from the cell.
Apoptotic bodies are released from blebbing cells undergoing apoptosis
(Colombo et al., 2014).
EV research is a rapidly evolving and expanding field, and it appears
that all biological fluids contain very large numbers of EVs; they are
produced from all cells that have been studied to date, and are known
to have roles in several reproductive processes. EVs have been de-
monstrated to be involved in modulating the immune system and their
immunological effects comprise a broad range of mechanisms, in-
cluding immune activation, immune suppression, and modulation of
immune surveillance (Admyre et al., 2003; Gutiérrez-Vázquez et al.,
2013; Pugholm et al., 2016; van der Vlist et al., 2012). Also during the
early stages of the human reproductive process, the EVs from the
ovarian follicle, seminal fluid, endometrium, embryo and trophoblast
cells have shown potential to modulate maternal immune function lo-
cally (Redman and Sargent, 2007). During later pregnancy, the placenta
is the primary source of EVs and the syncytiotrophoblast releases EVs
directly into the maternal blood constituting a major signaling me-
chanism and maternal immune sensing of the fetus (Tannetta et al.,
2014). Lately, it has also been found that EVs can cause functional in-
flammatory changes, and induce labor and delivery (Sheller-Miller
et al., 2019).
Pregnancy is shown to cause an up to 50-fold increase in numbers of
circulating exosomes, and placenta-derived exosomes are known to be
present in maternal blood (Mincheva-Nilsson and Baranov, 2014;
Mitchell et al., 2015; Salomon et al., 2014). In general, EVs are thought
to be anti-inflammatory or tolerogenic upon uptake into recipient cells
(Mincheva-Nilsson and Baranov, 2014). Therefore, placental EVs may
play an important role in maternal-fetal tolerance and therefore also in
relation to RPL (Stefanski et al., 2019). Pregnancy complications are
hypothesized to have their origin in disorders of the early placentation
(Mitchell et al., 2015). If these changes affect the placenta this would
arguably affect EV production during early pregnancy. Women at risk
of developing pregnancy complications, such as RPL patients, might
benefit from identification of changes in the EV secretion and thereby
provide an opportunity to develop clinically useful early pregnancy
screening biomarkers.
In this study, plasma collected from 39 women with RPL from the
study of Christiansen et al. (2002) were investigated using the Extra-
cellular Vesicle Array (EV Array). The sampling of plasma was per-
formed consecutively (from gestational week (GW) 5) and the protein
phenotypes of the smaller EVs (sEVs) in plasma were analyzed for the
presence of 34 markers of interest. The levels of sEVs or changes in their
levels in early pregnancy were correlated with treatment groups (IVIG
or placebo).
The Extracellular Vesicle Array (EV Array) is a sandwich ELISA-
based method, which is optimized to catch and detect the smaller types
of EVs, such as exosomes and exosome-like vesicles, with a diameter up
to ∼150 nm. The capturing of sEVs is performed with the use of an
antibody panel targeting selected membrane- or membrane associated
proteins (Jørgensen et al., 2013). The EV Array constitutes a fast, au-
tomated, economical and highly sensitive method for exploration of
plasma-sEVs carrying CD9, CD63 and/or CD81.
2. Materials and methods
2.1. Patients included from the previous study
From the period June 1994 to June 1999, the placebo-controlled
trial by Christiansen et al. (Christiansen et al., 2002) included a total of
58 patients with RPL who met the criteria eligible for participation. In
short, the inclusion criteria were patients with four or more confirmed
PLs before the end of GW26, of which the last three were consecutive.
After inclusion, all patients were randomly assigned to either IVIG
or placebo treatment. These infusions were given double-blinded. For
intervention, Nordimmun (HemaSure A/S, Copenhagen, Denmark) was
used (human IgG prepared from plasma) containing human IgG, human
albumin, sucrose and sodium chloride, whereas the placebo contained
exclusively human albumin, sucrose and sodium chloride. The first
infusion was given at GW5 and weekly infusions were given from GW5
to GW10, and afterwards every second week until GW26 or until time
of miscarriage. Blood samples were drawn in EDTA tubes before each
infusion of study drug, they were immediately centrifuged (standard
protocol) and the extracted plasma was stored after at −80 °C.
For the current analysis, 39 patients from the study met the criteria
set for data analysis in this study. Patients were included if at least two
stored plasma samples were available, the first at GW5 before initiation
of treatment and the next preferably from GW7. If patients did not have
a GW7 plasma sample, another sample ±1 GW was chosen. Thereby,
the interval for the second plasma sample became GW6-8.
2.2. Antibodies used
General EV markers: CD9 and CD81 (Ancell Corporation, MN, USA);
CD63 (Bio-Rad, CA, USA); Flotillin-1 and TSG101 (Abcam, GB); Alix
(clone 3A9, Biolegend, CA, USA).
Placental markers and hormone receptors: PLAP (clone 8B6, Santa
Cruz Bio, TX, USA,); FSHR (clone 626717), Adenosine A2a R (clone
599717) (R&D Systems, MN, USA); LHR (clone 8G9A2), TSHR (clone
49), OPRL1 (Novus Biologicals, CO; USA); ADRB2 (clone 13A16),
CHRM1, 3, 4 and 5 (LifeSpan Biosciences, WA, USA); CHRM2 (Boster
Biological Technology, CA, USA).
Immune- and blood markers: CD4 (clone 34930), CD8a (clone
37006), CD45 (clone 2D1), MIC A/B (clone 159207), TRAIL (clone
75411)(R&D Systems); HLA ABC (clone W6/32, Biolegend); HLA DR/
DP/DQ (clone HB-145, Loke Diagnostics Aps, DK); HLA-G (clone 87-G,
Novus Biologicals); CD276 (Sdix, DE, USA); CTLA4 (clone ANC152.2/
8H5, LifeSpan Biosciences); LFA1(clone HI111, Ab Biotec, CA, USA);
ICAM-1 (clone R6.5, ThermoFisher Scientific, MA, USA); PD-L1 (Sino
Biological, CH), FasL (clone 10F2, Bio-Rad, CA, USA).
Hypoxia markers: CAIX (Abcam), CAXII (clone 315601, R&D
Systems).
2.3. EV Array analysis
Microarray epoxysilane-coated slides (Nexterion® Slide E, SCHOTT,
DE) were customized by printing antibodies into micro-sized spots
using a SciFLEXARRAYER S12 (Scienion, DE). All antibodies were
printed in triplicates at a concentration of 200 μg/mL and for positive
controls biotinylated human IgG at 100 μg/mL was used in a spotting
buffer consisting of 5% glycerol in PBS, which were also used as ne-
gative control.
The analysis was performed as described by (Bæk and Jørgensen,
2017). First, the microarray slides were blocked with 50 mM ethano-
lamine, 0.1 M Tris, 0.1 % SDS, pH 9.0. The slides were mounted in
multi-well hybridization cassettes (ArrayIt Corporation, CA, USA) be-
fore applying the plasma samples. sEVs from 10 μL of plasma (diluted
1:10 in washing buffer; 0.2 % Tween20 in PBS) were captured onto the
microarray spot by an incubation at RT for two hours. Afterwards the
incubation was continued overnight at 4 °C. The slides were removed
M.M. Jørgensen, et al. Journal of Reproductive Immunology 140 (2020) 103128
2
from the multi-well cassettes and subjected to a washing procedure in
washing buffer for 10 min in a high-throughput washing station (Ar-
rayIt Corporation). To detect the captured sEVs the slides were then
incubated with a cocktail of biotinylated detection antibodies (anti-
human -CD9, -CD63 and -CD81, LifeSpan BioSciences) diluted in wash-
buffer (1:1,500) for two hours at RT. Afterwards; the slides were wa-
shed for 10 min before adding streptavidin-Cy5 (ThermoFisher Scien-
tific) diluted 1:1,500 in washing buffer. After a 30 min incubation, the
slides were washed for 10 min in washing buffer, and then a 10 min
wash in deionized water and lastly dried using a Microarray High-Speed
Centrifuge (ArrayIt Corporation).
Scanning of the microarray slides and spot detection of the antibody
markers by fluorescence readout was performed using an Innoscan
710AL (Innopsys, FR) as described by (Bæk and Jørgensen, 2017).
Image analysis and calculation of total fluorescence intensity were
performed using Mapix v. 8.3 (Innopsys).
2.4. Statistical analysis
Descriptive data were expressed as mean, standard deviation (SD),
and percentage in Table 1.
Non-parametric Mann-Whitney tests were used to compare the in-
fluence of IVIG vs placebo treatment by analyzing the differences be-
tween the samples taken before (GW5) and after initiation of treatment
(GW6-8). Differences between groups were assessed by the Mann-
Whithey rank sum test. All p values were two-sided. To adjust for
multiple comparisons, Bonferroni correction was applied and only p
values less than 0.0015 were considered significant (α = 0.05/34 EV
markers = 0.0015).
Statistical calculations were performed using GraphPad Prism ver.
6.07 (GraphPad Software Inc. CA, US), and StataIC ver. 14.2
(StataCorp, TX, US).
3. Results
To characterize the phenotypes of sEVs an EV Array analysis was
performed on plasma from 39 pregnant women with RPL. The char-
acteristics of these women include age, number of previous pregnancy
losses, treatment with IVIG or placebo and outcome of the pregnancy in
the randomized trial; the distribution is presented in Table 1.
3.1. Influence of IVIG treatment on the contents of EVs in plasma
Thirty-four different antibodies were printed in triplicates and used
to captures and analyze the content of sEVs in 10 μL of unpurified
plasma. The protein profiles of 34 surface- or surface-associated mar-
kers on the sEVs were analyzed and the results are presented with re-
ference to GW5 in Fig. 1 and Supplemental Figs. 1 and 2.
The study included 39 patients with RPL of which 19 were given
IVIG infusions and 20 were given placebo. Fig. 1 illustrates the effects of
treatment on the plasma sEV contents throughout GW5 to GW15. Each
patient had an individual response, but there is a clear tendency that
the IVIG treatment contributes to an increase in the sEV contents ra-
pidly after the first infusion, as seen for the EV markers CD9, CD63 and
CD81. This effect was not seen for the patients treated with placebo,
where the contents of several EV markers tended to decrease, as seen
for Flotillin-1. The most pronounced increases (seen for the placental
marker PLAP) and decreases are visibly seen within the very early
Table 1
Baseline characteristics of the women included in this study.
IVIG treatment (n =
19)
Placebo (n = 20)
Age (years)a 31.6 (3.8) 31.5 (4.8)
Number of previous pregnancy
losses
4 12 (63.2 %) 16 (80.0 %)
5 5 (26.3 %) 1 (5.0 %)
6 1 (5.3 %) 2 (10.0 %)
8 1 (5.3 %)
10 1 (5.0 %)
Outcome
Livebirth 10 (52.6 %) 12 (60.0 %)
Pregnancy loss 9 (47.4 %) 8 (40.0 %)
a mean (SD).
Fig. 1. The changes in sEV content for each individual patient during GW5 to
GW15 with reference to GW5 (before initiation of treatment). The log2 trans-
formed signal values are shown for individuals treated with IVIG (left panel,
blue) or placebo (right panel, green). The profiles for the protein markers CD9,
CD63, CD81, PLAP and Flotillin-1 are shown.
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pregnancy (GW5-7). As the sampling of the blood were not consistently
in time, it was chosen to perform the subsequent statistical analyses on
the samples taken before initiation of treatment (GW5) and 1–3 weeks
(GW6-8) after the first treatment. The influence of the infusions with
IVIG is prominently seen as an increase in several sEV markers in
Fig. 2A and for most of the markers (27 of 34) significant changes (p<
0.0015) were identified when performing a non-parametric comparison
of the differences between the treatments (Fig. 2B and Table 2). Some of
the general EV markers increased significantly (CD63, CD81 and Alix)
whereas CD9 and Flotillin-1 did not. The placental marker PLAP
showed the highest mean increase (6-fold higher) in patients treated
with IVIG compared with patients treated with placebo.
4. Discussion
Investigating plasma sEVs during pregnancy can probably help to
understand the different processes occurring during fetal development
and the fetus-maternal interaction. To determine the levels and phe-
notypes of sEVs in plasma from patients with RPL, the established
protein microarray-based analysis EV Array was used. The EV Array is
optimized to catch and detect the smaller types of EVs, such as exo-
somes and exosome-like vesicles, with diameters up to ∼150 nm.
Several studies have investigated the content of circulating EVs
throughout pregnancy (Carp et al., 2004; Germain et al., 2007; Mitchell
et al., 2015; Sabapatha et al., 2006; Salomon et al., 2014; Sarker et al.,
2014; Sheller-Miller et al., 2019). All the studies identify that the
plasma levels of EVs in general and in particular placenta-derived EVs,
increases towards term. The used purification and detection methods
differs between the studies, which makes it difficult to compare the
results directly across the studies. A general conclusion though is that
the increase in EV levels correlate with the mean uterine artery blood
flow and at delivery with the placental weight. In the study of Miranda
et al. (2018) they found that the proportion of circulating placental EVs
compared to the total level of EVs was significantly reduced in small
fetuses as compared to controls, and that the level of CD63 positive EVs
is an indicator of fetal growth (Miranda et al., 2018).
The present study focused only on the early phase of the pregnancy
(GW5 to GW15) and for the group of patients receiving placebo the
levels of sEVs in plasma were not found to increase significantly, as seen
in Fig. 1. This is partially in contrast to the above mentioned studies
although the small dimensions of the fetus and the placenta this early in
pregnancy should be taken into considerations.
We could not identify any studies investigating the relationship
between sEVs and RPL, though several studies have investigated mi-
croparticles (MPs) in women with this complication (Alijotas-Reig
et al., 2011; Carp et al., 2004; Kaptan et al., 2008; Laude et al., 2001).
These studies used different methods such as flow cytometry and it can
therefore be difficult to compare the findings as the use of non-stan-
dardized methods compromise comparative analysis.
Treatment with IVIG inhibits activation and functions of various
innate immune cells such as DCs, monocytes, macrophages, neutrophils
and NK cells. It neutralizes activated complement components. In ad-
dition, IVIG modulates B-cell functions and plasma cells (Pl), re-
ciprocally regulates Treg cells and effector T cells such as Th 1 and Th
17 subsets and down-regulates the production of inflammatory cyto-
kines (Galeotti et al., 2018). In this study, statistically significant higher
levels of sEVs were found in the IVIG treated patients compared with
the group receiving placebo with respect to 27 out of 34 markers. These
findings suggest that treatment with IVIG contributes to an increased
concentration of sEVs in plasma of pregnant patients with RPL.
This phenomenon of an overall increase in the levels of sEVs might
be based on a systemic effect as IVIG has several immunomodulatory
effects involving cytokines, the complement system and inflammatory
cells, as well as the fact that one of the ways inflammatory cells exert
immunomodulation is by secretion of EVs (Zhang et al., 2017). Al-
though many studies have reported the anti-inflammatory function of
IVIG therapy, the underlying mechanisms are not completely under-
stood and the effect on the production of EVs has not been elucidated in
detail. In patients with Kawasaki disease, Zhang et al. (2017) in-
vestigated the protein profiles of plasma exosomes before and after
treatment with IVIG and found that the treatment reduced the acute-
phase response and boosted complement activation, innate immune
response, and antibacterial humoral response. Similar results are in-
dicated in the present study, as it seems that treatment with IVIG boosts
the production of sEVs in general, but also from the panel of immune
markers investigated.
It could be questioned whether the increase in the levels of sEVs
after IVIG is caused by sEVs contained in the IVIG product
(Nordimmun) given. It has not been possible to test the product as it has
unfortunately gone out of production, but during production, the IgG
underwent an affinity purification after which it is believed that the
product does not contain any sEVs.
The highest influence on the IVIG treatment were identified on sEVs
Fig. 2. The sEV contents of the protein markers CD9, PLAP, Flotillin-1 and Alix
are shown as log2 transformed relative intensities and the differences between
the samples taken before (GW5) and after (GW6-8) treatment. A) Log2 trans-
formed relative intensities for the individuals before and after treatment (either
IVIG (blue) or placebo (green)). B) Differences between the samples taken be-
fore and after treatment. Mean ± SD is shown and significant differences are
marked with asterisks, p < 0.0015 (*); p < 0.0003 (**).
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carrying the placental marker PLAP, which showed a 6-fold increase. It
could indicate that IVIG in particular binds to and interact with tro-
phoblast cells when given to pregnant women causing a pronounced
release of sEVs with placenta-specific markers.
The plasma samples used for this study have been stored at −80 °C
for approximately 20 years. This long time storage should be taken into
consideration, as there are no knowledge on how storage affects the
sEVs. However, previous studies by Bæk et al., 2016 showed that the
phenotypes of sEVs in plasma were not significantly affected by storage
at −80 °C for several months (Bæk et al., 2016).
4.1. Conclusive remarks
Prevention of fetal rejection, in part by the suppression of maternal
cell-mediated immune responses, has long been recognized. Evidence
increasingly indicates that placental EVs form part of a range of im-
munosuppressive factors released by the placenta which are involved in
this process (Tannetta et al., 2014). We used the EV Array microarray
technology to analyze the protein profiles of sEVs in plasma of pregnant
women with RPL. The findings in this study strongly demonstrate that
treatment with high-doses of IVIG boosts the production and release of
almost all types of EVs and in particular placental-derived sEVs into the
circulation during pregnancy; however, the biological role of this boost
remains to be clarified in further studies relating sEV protein profiles to
subsequent pregnancy outcome.
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